# Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct01974661/  
OnCo record `nct01974661` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Ilixadencel run by Mendus, completed.

## Summary

Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT01974661 by Mendus, with 18 participants enrolled, started 2013-10. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: COMBIG-DC (ilixadencel).

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01974661
- Phase: 1
- Setting: A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma
- Sponsor: Mendus
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT01974661: https://clinicaltrials.gov/study/NCT01974661

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Ilixadencel](https://onco.cc/drugs/ilixadencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct01974661.json